Manufacturing & Packaging

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.

The deal is expected to be finalized by the first half of this year.

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia.

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

A total of 140 companies are being placed on the Entity List, in an effort to limit China’s effectiveness in the sector.

The transaction reaffirms the CDMO’s interest in growth on a global scale.

Why well-organized documentation is critical at every stage of the process.

The CDMO’s offerings will now feature automated fill-finish.

The CDMO's California facility welcomes new production suites, a revamp of its development labs, and more.

The CDMO is investing $3.6 million toward boosting its advanced labeling, automated visual inspection, and fill-finish tech.

One packaging aspect—the tape—is often overlooked, but is a valuable component of the shipping process.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, describes how events such as the East and Gulf Coast port strikes have brought to light the differences between branded and generic pharmaceuticals.

With the design of the new 360,000 square-foot building, the CDMO’s goal is to continue to modernize its Laupheim site.

With the implementation of unit-level traceability, the collaboration is expected to provide additional visibility not only within the aseptic manufacturing process, but the entire supply chain overall.

The goal is to provide greater access to HIV prevention drugs in low-income countries.

Why it's critical for companies to set long-term, strategic goals in their journeys toward decarbonization.

New facilities are expected to focus on manufacturing next-generation medicines and biologic medicines.

It’s essential for commercial success, but presents its share of obstacles.

The project is funded by Scottish Enterprise, and aims to boost commercial manufacturing of injectable drug product.

The enhancement—which complements the CDMO’s adeno-associated viral vector services—will be utilized at the company’s advanced therapies site in Stevenage, UK.

The project features several enhancements, including a new 67,000 square-foot warehouse at its HQ.

The company also participated in the coalition’s pilot inspection program, making it the first CDMO to do so.

Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.

The 86,000 square-foot Køge facility will be fully functional by 2027.

The facility will focus on furthering RNA and DNA-based therapies.

Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.

The CDMO will also be adding new equipment for the manufacture of oligonucleotides and peptides.

The parties’ combined portfolio help tackle the rising demand for advanced cell and gene therapies.